Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study | Citedby Results | Cancer Research Communications | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study

Cancer Research Communications (2022) 2 (11): 1426–1435.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)

Takayuki Irie
Masaaki Sawa

Expert Opinion on Therapeutic Patents (2023) 33 (7-8): 493.

CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade

Tomoko Yamamori Morita
Jie Yu
Yukie Kashima
Ryo Kamata
Gaku Yamamoto
Tatsunori Minamide
Chiaki Mashima
Miyuki Yoshiya
Yuta Sakae
Toyohiro Yamauchi
Yumi Hakozaki
Shun-ichiro Kageyama
Akito Nakamura
Eric Lightcap
Kosuke Tanaka
Huifeng Niu
Karuppiah Kannan
Akihiro Ohashi

Nature Communications (2023) 14 (1)

The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies

George Mihai Nitulescu
Gheorghe Stancov
Oana Cristina Seremet
Georgiana Nitulescu
Dragos Paul Mihai
Cosmina Gabriela Duta-Bratu
Stefania Felicia Barbuceanu
Octavian Tudorel Olaru

Molecules (2023) 28 (14): 5359.